0001181431-11-030133.txt : 20110516 0001181431-11-030133.hdr.sgml : 20110516 20110516173439 ACCESSION NUMBER: 0001181431-11-030133 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20110512 FILED AS OF DATE: 20110516 DATE AS OF CHANGE: 20110516 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cole Douglas G. CENTRAL INDEX KEY: 0001486373 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34655 FILM NUMBER: 11848970 MAIL ADDRESS: STREET 1: AVEO PHARMACEUTICALS, INC. STREET 2: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVEO PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001325879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172995000 MAIL ADDRESS: STREET 1: 75 SIDNEY STREET STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 rrd311872.xml COLE FORM 4 X0303 4 2011-05-12 0 0001325879 AVEO PHARMACEUTICALS INC AVEO 0001486373 Cole Douglas G. C/O AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE MA 02139 1 0 0 0 Common Stock 2011-05-12 4 S 0 919 17.3033 D 31540 I by AGTC Advisors Fund, L.P. Common Stock 2011-05-12 4 S 0 15200 17.3033 D 521815 I by Applied Genomic Technology Capital Fund, L.P. Common Stock 2011-05-13 4 S 0 4639 17.7517 D 26901 I by AGTC Advisors Fund, L.P. Common Stock 2011-05-13 4 S 0 76750 17.7518 D 445065 I by Applied Genomic Technology Capital Fund, L.P. Common Stock 2011-05-16 4 S 0 2992 17.9772 D 23909 I by AGTC Advisors Fund, L.P. Common Stock 2011-05-16 4 S 0 49500 17.9773 D 395565 I by Applied Genomic Technology Capital Fund, L.P. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by AGTC Advisors Fund, L.P. on November 9, 2010. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.30 to $17.32, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. Held by AGTC Advisors Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen Inc.") is the general partner of AGTC Partners, L.P., which is the general partner of AGTC Advisors Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc. ("Flagship Inc."). Noubar B. Ayefan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and may be deemed to have beneficial ownership with respect to all shares held by AGTC Advisors Fund, L.P. The reporting person disclaims beneficial owenrship over shares held by AGTC Advisors Fund, L.P. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Applied Genomic Technology Capital Fund, L.P. on November 9, 2010 Held by Applied Genomic Technology Capital Fund, L.P.; NewcoGen Group, Inc. ("NewcoGen") is the general partner of AGTC Partners, L.P., which is the general partner of Applied Genomic Technology Capital Fund, L.P. NewcoGen Inc. is a wholly-owned subsidiary of Flagship Ventures Management, Inc.("Flagship"). Noubar B. Afeyan Ph.D. and Edwin M. Kania, Jr. are the directors of Flagship Inc. and they may be deemed to have beneficial ownership with respect to all shares held by Applied Genomic Technology Capital Fund, L.P. The reporting person disclaims beneficial ownership over shares held by Applied Genomic Technology Capital Fund, L.P. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.30 to $18.10, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.68 to $18.52, inclusive. The reporting person undertakes to provide AVEO Pharmaceuticals, Inc., any security holder of AVEO Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote. /s/ Joseph D. Vittiglio, Esq, attorney-in-fact 2011-05-16